Home LiteratureArticle Details
PMID: 31795960 Published · epublish English Comparative Study Journal Article Meta-Analysis

Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.

BMC cancer ·Vol. 19 ·No. 1 ·2019-12-03 ·Pages 1175

Chhatriya B, Mukherjee M, Ray S, Sarkar P, Chatterjee S, Nath D, Das K, Goswami S

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is considered as one of the most aggressive cancers lacking efficient early detection biomarkers. Circulating miRNAs are now being considered to have potency to be used as diagnostic and prognostic biomarkers in different diseases as well as cancers. In case of cancer, a fraction of the circulating miRNAs is actually derived from the tumour tissue. This fraction would function as stable biomarker for the disease and also would contribute to the understanding of the disease development. There are not many studies exploring this aspect in pancreatic cancer and even there is not much overlap of results between existing studies. In order to address that gap, we performed a miRNA microarray analysis to identify differentially expressed circulating miRNAs between PDAC patients and normal healthy individuals and also found two more similar datasets to perform a meta-analysis using a total of 182 PDAC patients and 170 normal, identifying a set of miRNAs significantly altered in patient serum. Next, we found five datasets studying miRNA expression profile in tumour tissues of PDAC patients as compared to normal pancreas and performed a second meta-analysis using data from a total of 183 pancreatic tumour and 47 normal pancreas to detect significantly deregulated miRNAs in pancreatic carcinoma. Comparison of these two lists and subsequent search for their target genes which were also deregulated in PDAC in inverse direction to miRNAs was done followed by investigation of their role in disease development. We identified 21 miRNAs altered in both pancreatic tumour tissue and serum. While deciphering the functions of their target genes, we characterized key miR-Gene interactions perturbing the biological pathways. We identified important cancer related pathways, pancreas specific pathways, AGE-RAGE signaling, prolactin signaling and insulin resistance signaling pathways among the most affected ones. We also reported the possible involvement of crucial transcription factors in the process. Our study identified a unique meta-signature of 21 miRNAs capable of explaining pancreatic carcinogenesis and possibly holding the potential to act as biomarker for the disease detection which could be explored further.

Keywords
Meta-analysis Pancreatic ductal adenocarcinoma Serum Tumour microRNA
MeSH Terms
Biomarkers, Tumor/blood,genetics Carcinoma, Pancreatic Ductal/blood,genetics,pathology Circulating MicroRNA/blood,genetics Humans MicroRNAs/blood,genetics Pancreatic Neoplasms/blood,genetics,pathology
Chemicals
Biomarkers, Tumor Circulating MicroRNA MicroRNAs
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Chhatriya Bishnupriya
National Institute of Biomedical Genomics, Kalyani, West Bengal, India.
Mukherjee Moumita
National Institute of Biomedical Genomics, Kalyani, West Bengal, India.
Ray Sukanta
School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
Sarkar Piyali
Present Address: Tata Medical Centre, Kolkata, West Bengal, India.
Chatterjee Shatakshee
National Institute of Biomedical Genomics, Kalyani, West Bengal, India.
Nath Debashis
Indira Gandhi Memorial Hospital, Agartala, Tripura, India.
Das Kshaunish
School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
Goswami Srikanta ORCID
National Institute of Biomedical Genomics, Kalyani, West Bengal, India. [email protected].
References (99)
99 references, click to expand
  1. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.
    Adv Exp Med Biol. 2015;889:71-87 PMID: 26658997
  2. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer.
    Int J Biol Sci. 2016 Jan 28;12(3):326-37 PMID: 26929739
  3. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis.
    Surgery. 2011 Nov;150(5):916-22 PMID: 22018284
  4. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.
    Mod Pathol. 2012 Dec;25(12):1609-22 PMID: 22878649
  5. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.
    Cancer Res. 2017 Oct 1;77(19):5313-5326 PMID: 28807937
  6. The Pancreatic Expression database: 2011 update.
    Nucleic Acids Res. 2011 Jan;39(Database issue):D1023-8 PMID: 20959292
  7. A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer.
    Oncotarget. 2016 Oct 25;7(43):69616-69624 PMID: 27626307
  8. Characterization of gene expression and activated signaling pathways in solid-pseudopapillary neoplasm of pancreas.
    Mod Pathol. 2014 Apr;27(4):580-93 PMID: 24072181
  9. Novel blood-based microRNA biomarker panel for early diagnosis of chronic pancreatitis.
    Sci Rep. 2017 Jan 11;7:40019 PMID: 28074846
  10. Proteomics. Tissue-based map of the human proteome.
    Science. 2015 Jan 23;347(6220):1260419 PMID: 25613900
  11. Significance of microRNA-based biomarkers for pancreatic cancer.
    Ann Transl Med. 2015 Oct;3(18):277 PMID: 26605323
  12. TcoF-DB v2: update of the database of human and mouse transcription co-factors and transcription factor interactions.
    Nucleic Acids Res. 2017 Jan 4;45(D1):D145-D150 PMID: 27789689
  13. miRNet-Functional Analysis and Visual Exploration of miRNA-Target Interactions in a Network Context.
    Methods Mol Biol. 2018;1819:215-233 PMID: 30421406
  14. MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling.
    Exp Cell Res. 2018 Jan 15;362(2):268-278 PMID: 29174979
  15. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue.
    PLoS One. 2012;7(4):e34151 PMID: 22511932
  16. ETS-family genes in pancreatic development.
    Dev Dyn. 2007 Nov;236(11):3100-10 PMID: 17907201
  17. P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1.
    Int J Cancer. 2017 Nov 1;141(9):1879-1890 PMID: 28656629
  18. MicroRNA-191 promotes pancreatic cancer progression by targeting USP10.
    Tumour Biol. 2014 Dec;35(12):12157-63 PMID: 25168367
  19. miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer.
    Mol Cancer. 2017 Oct 27;16(1):167 PMID: 29078789
  20. The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products.
    Oncoimmunology. 2013 May 1;2(5):e24184 PMID: 23762800
  21. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies.
    Diabetologia. 2011 Mar;54(3):527-34 PMID: 21116605
  22. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.
    BMC Bioinformatics. 2013 Apr 15;14:128 PMID: 23586463
  23. ExoCarta 2012: database of exosomal proteins, RNA and lipids.
    Nucleic Acids Res. 2012 Jan;40(Database issue):D1241-4 PMID: 21989406
  24. MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene.
    Ann Surg Oncol. 2012 Jul;19(7):2394-402 PMID: 22407312
  25. Prolactin and cancer: Has the orphan finally found a home?
    Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S195-8 PMID: 23565377
  26. Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells.
    Genes Chromosomes Cancer. 2012 Jun;51(6):557-68 PMID: 22344632
  27. Unfolded protein response in cancer: the physician's perspective.
    J Hematol Oncol. 2011 Feb 23;4:8 PMID: 21345215
  28. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance.
    Pancreas. 2013 Jan;42(1):67-71 PMID: 22850622
  29. ExoCarta as a resource for exosomal research.
    J Extracell Vesicles. 2012 Apr 16;1:null PMID: 24009883
  30. The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival.
    PLoS One. 2013 Oct 08;8(10):e76450 PMID: 24116110
  31. ExoCarta: A compendium of exosomal proteins and RNA.
    Proteomics. 2009 Nov;9(21):4997-5000 PMID: 19810033
  32. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.
    Cancer Prev Res (Phila). 2009 Sep;2(9):807-13 PMID: 19723895
  33. Loss of miR-126 is crucial to pancreatic cancer progression.
    Expert Rev Anticancer Ther. 2012 Jul;12(7):881-4 PMID: 22845403
  34. RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets?
    Neoplasma. 2015;62(3):353-64 PMID: 25967358
  35. GeneMANIA update 2018.
    Nucleic Acids Res. 2018 Jul 2;46(W1):W60-W64 PMID: 29912392
  36. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer.
    Transl Oncol. 2010 Apr;3(2):109-13 PMID: 20360935
  37. Mirna expression profiles identify drivers in colorectal and pancreatic cancers.
    PLoS One. 2012;7(3):e33663 PMID: 22479426
  38. Overexpression of HOXC11 homeobox gene in clear cell renal cell carcinoma induces cellular proliferation and is associated with poor prognosis.
    Tumour Biol. 2015 Apr;36(4):2821-9 PMID: 25476856
  39. TRRUST: a reference database of human transcriptional regulatory interactions.
    Sci Rep. 2015 Jun 12;5:11432 PMID: 26066708
  40. MiR-652-3p is upregulated in non-small cell lung cancer and promotes proliferation and metastasis by directly targeting Lgl1.
    Oncotarget. 2016 Mar 29;7(13):16703-15 PMID: 26934648
  41. Prediction of DNA binding motifs from 3D models of transcription factors; identifying TLX3 regulated genes.
    Nucleic Acids Res. 2014 Dec 16;42(22):13500-12 PMID: 25428367
  42. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy.
    Elife. 2013 Jul 16;2:e00825 PMID: 23878725
  43. Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma.
    Onco Targets Ther. 2017 Nov 23;10:5591-5604 PMID: 29200874
  44. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer.
    Oncol Rep. 2014 Sep;32(3):979-88 PMID: 24968817
  45. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.
    Int J Cancer. 2015 Jun 1;136(11):2616-27 PMID: 25388097
  46. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
    Cancer Biol Ther. 2009 Nov;8(21):2013-24 PMID: 20037478
  47. Aberrant expression of microRNAs in serum may identify individuals with pancreatic cancer.
    Int J Clin Exp Med. 2014 Dec 15;7(12):5226-34 PMID: 25664025
  48. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis.
    Carcinogenesis. 2010 Mar;31(3):334-41 PMID: 20028726
  49. miRandola 2017: a curated knowledge base of non-invasive biomarkers.
    Nucleic Acids Res. 2018 Jan 4;46(D1):D354-D359 PMID: 29036351
  50. Defective prolactin signaling impairs pancreatic β-cell development during the perinatal period.
    Am J Physiol Endocrinol Metab. 2013 Nov 15;305(10):E1309-18 PMID: 24064341
  51. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function.
    Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20 PMID: 20576703
  52. miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1.
    Pathol Res Pract. 2018 Sep;214(9):1388-1394 PMID: 30098829
  53. Cytoscape: a software environment for integrated models of biomolecular interaction networks.
    Genome Res. 2003 Nov;13(11):2498-504 PMID: 14597658
  54. A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells.
    J Transl Med. 2017 Oct 19;15(1):211 PMID: 29052509
  55. MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells.
    Sci Rep. 2016 Jun 09;6:27641 PMID: 27279541
  56. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9.
    Mol Cancer Res. 2012 Jan;10(1):3-10 PMID: 22064652
  57. RAGE and RAGE ligands in cancer.
    Curr Mol Med. 2007 Dec;7(8):777-89 PMID: 18331236
  58. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.
    Br J Cancer. 2014 Oct 14;111(8):1572-80 PMID: 25117811
  59. MiR-103a-3p targets the 5' UTR of GPRC5A in pancreatic cells.
    RNA. 2014 Sep;20(9):1431-9 PMID: 24984703
  60. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
    Oncotarget. 2015 Nov 24;6(37):39661-75 PMID: 26498682
  61. MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers.
    PLoS One. 2015 Feb 23;10(2):e0118220 PMID: 25706130
  62. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.
    Breast Cancer Res. 2008;10(4):R68 PMID: 18681966
  63. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010.
    Sci Rep. 2014 Oct 23;4:6747 PMID: 25339498
  64. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.
    Mod Pathol. 2012 Jan;25(1):112-21 PMID: 21983937
  65. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis.
    Clin Cancer Res. 2012 Aug 15;18(16):4356-64 PMID: 22718861
  66. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer.
    Biomark Res. 2016 Oct 22;4:20 PMID: 27795830
  67. MicroRNA in pancreatic cancer.
    J Hum Genet. 2017 Jan;62(1):33-40 PMID: 27251005
  68. MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.
    Gastroenterology. 2014 Jan;146(1):268-77.e18 PMID: 24120476
  69. RNA Biomarkers: Frontier of Precision Medicine for Cancer.
    Noncoding RNA. 2017 Feb 20;3(1):null PMID: 29657281
  70. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions.
    Nucleic Acids Res. 2018 Jan 4;46(D1):D380-D386 PMID: 29087512
  71. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.
    JAMA. 2005 Dec 14;294(22):2872-8 PMID: 16352795
  72. RankProd 2.0: a refactored bioconductor package for detecting differentially expressed features in molecular profiling datasets.
    Bioinformatics. 2017 Sep 1;33(17):2774-2775 PMID: 28481966
  73. Exosome and exosomal microRNA: trafficking, sorting, and function.
    Genomics Proteomics Bioinformatics. 2015 Feb;13(1):17-24 PMID: 25724326
  74. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis.
    Bioinformatics. 2006 Nov 15;22(22):2825-7 PMID: 16982708
  75. Expression of prolactin and its receptor in human breast carcinoma.
    Endocrinology. 1997 Dec;138(12):5555-60 PMID: 9389544
  76. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.
    Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7 PMID: 27141961
  77. The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
    Curr Mol Med. 2016;16(1):70-82 PMID: 26695693
  78. MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation.
    Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17892-7 PMID: 24114270
  79. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.
    World J Gastrointest Oncol. 2016 Jan 15;8(1):18-29 PMID: 26798434
  80. MicroRNA-mediated regulation of pancreatic cancer cell proliferation.
    Oncol Lett. 2010 May;1(3):565-568 PMID: 22966344
  81. The links between insulin resistance, diabetes, and cancer.
    Curr Diab Rep. 2013 Apr;13(2):213-22 PMID: 23271574
  82. TcoF-DB: dragon database for human transcription co-factors and transcription factor interacting proteins.
    Nucleic Acids Res. 2011 Jan;39(Database issue):D106-10 PMID: 20965969
  83. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    PLoS One. 2015 Nov 25;10(11):e0143755 PMID: 26606261
  84. The pancreatic expression database: recent extensions and updates.
    Nucleic Acids Res. 2014 Jan;42(Database issue):D944-9 PMID: 24163255
  85. Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma.
    J Hum Genet. 2016 Feb;61(2):109-18 PMID: 26490187
  86. Effects of miR-16 plus CA19-9 detections on pancreatic cancer diagnostic performance.
    Clin Lab. 2014;60(1):73-7 PMID: 24600978
  87. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
    Clin Cancer Res. 2012 Jan 15;18(2):534-45 PMID: 22114136
  88. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer.
    Br J Cancer. 2012 Oct 9;107(8):1354-60 PMID: 22929886
  89. Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer.
    Br J Cancer. 2016 Jul 26;115(3):354-63 PMID: 27310702
  90. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
    Cancer Res. 2010 Feb 15;70(4):1585-94 PMID: 20145129
  91. Amplification of the prolactin receptor gene in mammary lobular neoplasia.
    Breast Cancer Res Treat. 2011 Jul;128(1):31-40 PMID: 20658264
  92. ExoCarta: A Web-Based Compendium of Exosomal Cargo.
    J Mol Biol. 2016 Feb 22;428(4):688-692 PMID: 26434508
  93. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
    Cancer Res. 2009 Apr 1;69(7):3165-72 PMID: 19276348
  94. Induction, modulation and potential targets of miR-210 in pancreatic cancer cells.
    Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):319-24 PMID: 22672828
  95. Integrative survival-based molecular profiling of human pancreatic cancer.
    Clin Cancer Res. 2012 Mar 1;18(5):1352-63 PMID: 22261810
  96. miRNet - dissecting miRNA-target interactions and functional associations through network-based visual analysis.
    Nucleic Acids Res. 2016 Jul 8;44(W1):W135-41 PMID: 27105848
  97. miR-210 regulates the interaction between pancreatic cancer cells and stellate cells.
    Biochem Biophys Res Commun. 2013 Aug 2;437(3):433-9 PMID: 23831622
  98. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer.
    J Gastrointest Surg. 2012 Jan;16(1):104-12; discussion 112 PMID: 22052106
  99. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.
    Indian J Surg Oncol. 2011 Jun;2(2):88-100 PMID: 22693400
Article Info
Journal
BMC cancer
Abbr.
BMC Cancer
ISSN
1471-2407
DOI
10.1186/s12885-019-6380-z
Email
[email protected]
Published
2019-12-03
Epub
2019-00-03
Pages
1175
Language
English
Region
England
NLM ID
100967800
PMCID
PMC6891989
Subset
IM
Grants
Department of Biotechnology, Government of India · BT/231/NE/TBP/2011
External Links
PubMed source DOI: 10.1186/s12885-019-6380-z PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2